Search

Your search keyword '"T cells -- Health aspects"' showing total 735 results
Start Over Descriptor "T cells -- Health aspects" Topic immunotherapy -- health aspects
735 results on '"T cells -- Health aspects"'

1. Findings from Sichuan University Provide New Insights into Cancer Therapy (Targeting Cd8+t Cells With Natural Products for Tumor Therapy: Revealing Insights Into the Mechanisms)

Subjects
T cells -- Health aspects, Antineoplastic agents -- Health aspects, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Physical fitness -- Health aspects, Antimitotic agents -- Health aspects, Health
Abstract

2024 JUL 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - Cancer Therapy. According [...]

Published
2024

2. Polyomavirus-positive Merkel cell carcinoma: the beginning of the beginning

Author

Wong, Michael K. and Yee, Cassian

Subjects
T cells -- Health aspects, Skin cancer -- Health aspects, Metastasis -- Health aspects, Antigenic determinants -- Health aspects, Immunotherapy -- Health aspects, Carcinoma -- Health aspects, Cancer -- Health aspects, Apoptosis -- Health aspects, Tumor antigens -- Health aspects, Health care industry
Abstract

Merkel cell carcinoma (MCC) is an aggressive, fast-growing, highly metastatic neuroendocrine skin cancer. The Merkel cell polyomavirus (MCPyV) is an oncogenic driver in the majority of MCC tumors. In this issue of the JCI, Hansen and authors report on their tracking of [CD8.sup.+] T cells reactive to MCPyV T antigen (T-Ag) in the peripheral blood of 26 patients with MCC who were undergoing frontline anti-programmed cell death protein-1 (anti-PD-1) immunotherapy. They discovered unique T cell epitopes and used the power of bar-coded tetramers to portray immune checkpoint inhibitor-induced immunogenicity as a predictor of clinical response. These findings provide the foundation for therapeutic possibilities for MCC, including vaccines and adoptive T cell- and T cell receptor-driven (TCR-driven) treatments., MCC is a rare and aggressive neuroendocrine tumor Merkel cell carcinoma (MCC) is an aggressive, fast-growing, highly metastatic neuroendocrine tumor. There are two pathways to the oncogenesis of MCC. One [...]

Published
2024
Full Text
View/download PDF

5. Dassault Systemes, CDR-Life collaborate to accelerate scientific innovation for cancer therapies

Subjects
Dassault Systemes S.A. -- Innovations, Computer software industry -- Innovations -- Health aspects, T cells -- Health aspects, Antineoplastic agents -- Innovations, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Antimitotic agents -- Innovations, Pharmaceuticals and cosmetics industries
Abstract

Dassault Systemes announced it collaborated with CDR-Life, a Swiss biotherapeutics company, to accelerate CDR-Life's development of next-generation highly tumour-selective immunotherapies using CDR-Life's proprietary M-gager platform. Scientists from Dassault Systemes' Contract [...]

Published
2024

6. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

7. Understanding CAR-T cell therapy for cancer: Mayo Clinic expert explains how it works

Subjects
Care and treatment, Health aspects, Cancer treatment -- Health aspects, Non-Hodgkin lymphomas -- Care and treatment, Cancer -- Care and treatment, Cancer research -- Health aspects, Immunotherapy -- Health aspects, T cells -- Health aspects, Oncology, Experimental -- Health aspects, Non-Hodgkin's lymphomas -- Care and treatment, Cancer -- Care and treatment -- Research
Abstract

World Lymphoma Day is September 15 ROCHESTER, Minn. -- For many doctors and researchers, https://www.mayo.edu/research/labs/discovery-translation-labs/cancer-research/cancer-immunotherapy that uses someone's own immune system to target and attack cancer cells is the next [...]

Published
2024

8. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

9. US FDA approves Iovance Biotherapeutics' Amtagvi for advanced melanoma

Subjects
United States. Food and Drug Administration, Gene mutations -- Health aspects, T cells -- Health aspects, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Drug approval -- Health aspects, Melanoma -- Drug therapy, Pharmaceuticals and cosmetics industries, Amtagvi (Medication) -- Health aspects
Abstract

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing and delivering novel polyclonal tumour infiltrating lymphocyte (TIL) cell therapies for patients with cancer, announced that the US Food and [...]

Published
2024

10. Emergex inks pact with DEKA to assess compatibility of Emergex's immunotherapeutic candidates with DEKA's intradermal therapeutic applicator

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Vaccines -- Health aspects, Pharmaceuticals and cosmetics industries
Abstract

Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of synthetic T cell-priming set-point immunotherapy-based treatment candidates, announced that the company has [...]

Published
2024

11. Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression

Author

Swatler, Julian, Ju, Young-Jun, Anderson, Ana C., and Lugli, Enrico

Subjects
T cells -- Health aspects, Tumors -- Health aspects, Corticosteroids -- Health aspects, Immunotherapy -- Health aspects, Metabolites -- Health aspects, B cells -- Health aspects, Enzymes -- Health aspects, Health care industry
Abstract

Suppression of antitumor immunity is a prominent feature of the tumor microenvironment. In this issue of the JCI, Taves, Otsuka, and authors show that glucocorticoids (GCs), which are potent immunosuppressive hormones mainly produced by the adrenals, can be reconverted from their inactive form to active metabolites via the 11[beta]-hydroxysteroid dehydrogenase type 1 (11[beta]-HSD1) enzyme expressed by murine tumor cell lines. In the tumor microenvironment, GCs acted on CD[4.sup.+] regulatory T cells to enhance their immunosuppressive function and promote tumor growth. The findings suggest that targeting GC recycling as a strategy for modulating tumor immunosuppression has the potential to improve therapeutic efficacy of immune checkpoint blockade., Glucocorticoids mediate immunosuppression Immunosuppression is a prominent feature of cancer development, restraining antitumor effector T cell responses and limiting efficacy of therapeutic interventions. Immunosuppression can be mediated by multiple mechanisms, [...]

Published
2023
Full Text
View/download PDF

12. New Cancer Therapy Data Have Been Reported by Researchers at Peking Union Medical College (Malic Enzyme 2 Maintains Metabolic State and Anti-tumor Immunity of Cd8++ T Cells)

Subjects
Peking Union Medical College, Oncology, Experimental -- Health aspects, T cells -- Health aspects, Antineoplastic agents -- Health aspects, Immunotherapy -- Health aspects, Cancer -- Health aspects -- Research, Enzymes -- Health aspects, Periodical publishing -- Health aspects, Antimitotic agents -- Health aspects, Cell Press
Abstract

2024 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on Drugs and Therapies - Cancer Therapy are presented in a new report. [...]

Published
2024

13. Research Conducted at Dana-Farber Cancer Institute Has Updated Our Knowledge about Influenza A Virus (Parsing Digital or Analog Tcr Performance Through Piconewton Forces)

Subjects
Oncology, Experimental -- Health aspects, T cells -- Health aspects, Immunotherapy -- Health aspects, Influenza -- Health aspects, Cancer -- Health aspects -- Research, Health
Abstract

2024 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on RNA Viruses - Influenza A Virus have been published. According to [...]

Published
2024

15. OLD CHEMO DRUG, NEW PANCREATIC CANCER THERAPY?

Subjects
T cells -- Health aspects, Antineoplastic agents -- Health aspects, Immunotherapy -- Health aspects, Chemotherapy -- Health aspects, Cancer -- Chemotherapy, Pancreatic cancer -- Drug therapy, Antimitotic agents -- Health aspects, News, opinion and commentary, Cold Spring Harbor Laboratory
Abstract

COLD SPRING HARBOR, NY -- The following information was released by Cold Spring Harbor Laboratory (CSHL): Pancreatic ductal adenocarcinoma (red) resists the body's immune response by surrounding itself with a [...]

Published
2024

16. Atara Biotherapeutics Unveils U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel(r)) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Subjects
United States. Food and Drug Administration, Transplantation of organs, tissues, etc. -- Health aspects, T cells -- Health aspects, Diseases -- Health aspects, Immunotherapy -- Health aspects, Chemotherapy -- Health aspects, Epstein-Barr virus -- Health aspects, Cancer -- Chemotherapy, General interest, News, opinion and commentary
Abstract

THOUSAND OAKS: Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and [...]

Published
2024

17. Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel[R]) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Diseases -- California, Drugs -- Prescribing, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Drug approval -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 [...]

Published
2024

18. New Car-T cancer therapy has risks as well as benefits

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Antineoplastic agents -- Health aspects, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Risk factors, Antimitotic agents -- Health aspects, Business, international
Abstract

London: Anglia Ruskin University has issued the following news release: In the last few decades, scientists have finally learned to harness the immune system to successfully treat cancer. Although doctors [...]

Published
2024

19. Report on 'Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030' released

Subjects
T cells -- Health aspects, Antineoplastic agents -- Product development, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Antimitotic agents -- Product development, General interest, News, opinion and commentary
Abstract

DUBLIN: The 'Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030' report has been added to ResearchAndMarkets.com's offering. After vicennium of futuristic T cells entrenched [...]

Published
2024

20. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

21. Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

22. Global Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Report 2024

Subjects
T cells -- Health aspects, Antineoplastic agents -- Product development, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Antimitotic agents -- Product development, General interest, News, opinion and commentary
Abstract

Dublin: The Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030 report has been added to ResearchAndMarkets.com's offering. After vicennium of futuristic T cells entrenched [...]

Published
2024

23. SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Tumors -- Care and treatment, Immunotherapy -- Health aspects, Papillomavirus infections -- Care and treatment, Drug approval -- Health aspects, Clinical trials -- Health aspects, Business, News, opinion and commentary
Abstract

SINGAPORE, June 30, 2024 /PRNewswire/-- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and [...]

Published
2024

24. Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Clinical trials -- Health aspects, General interest, News, opinion and commentary
Abstract

WARREN: Tevogen Bio Holdings Inc. ('Tevogen' or 'Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, reports [...]

Published
2024

25. Atara Biotherapeutics' Ebvallotm (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan|Rare Diseases

Subjects
T cells -- Health aspects, Diseases -- Health aspects, Immunotherapy -- Health aspects, General interest, News, opinion and commentary
Abstract

THOUSAND OAKS: ATARA BIOTHERAPEUTICS, INC has issued the following news release: Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform [...]

Published
2024

26. Atara Biotherapeutics' Ebvallo[TM] (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Subjects
T cells -- Health aspects, Diseases -- California, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Business, Business, international
Abstract

Ebvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell [...]

Published
2024

27. Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Hepatitis B -- Health aspects, Company business planning, Banking, finance and accounting industries, Business
Abstract

The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of [...]

Published
2024

28. iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, T cells -- Health aspects, Lupus -- Health aspects, Systemic lupus erythematosus -- Health aspects, Immunotherapy -- Health aspects, B cells -- Health aspects, Kidney diseases -- Health aspects, Business, Business, international
Abstract

New data demonstrate 92% of patients now meet DORIS complete remission criteria (mean 20 months follow up) iCell's BCMA CD19 cCAR was well tolerated; humoral immunity recovered in all LN [...]

Published
2024

29. Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Proteins -- Health aspects, General interest, News, opinion and commentary
Abstract

WARREN, N.J: Tevogen Bio Holdings Inc. retains activity against the currently dominant and highly mutated FLiRT strains of SARS-CoV-2 based on a review of this variant's protein sequences. Named FLiRT [...]

Published
2024

30. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

31. Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Banking, finance and accounting industries, Business
Abstract

WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=sPboWaZGlNhMm47RHUPHLyGLciNcb1ubDxA3h_OxyP2YovoDcM15bNRcHpLgjAM2TAXNnz4pi9VE93m1At5dRleGkN1-Nn9PizeD6-qStsA= ('Tevogen' or 'Tevogen Bio') (Nasdaq: https://www.globenewswire.com/Tracker?data=nohkfL5cRHoJ7rW9WwTXbpKAw96I3oBMzpXdfTLQ93scPMvCDhT9OeR2Ew-8bDVVjV88nTSuL0-nGZFTbez0rkAIgYBAgsz9V3gLUZNizQw=), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, [...]

Published
2024

32. Concerns about a revolutionary cancer therapy

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Antineoplastic agents -- Health aspects, Immunotherapy -- Health aspects, B cells -- Health aspects, Cancer -- Care and treatment, Antimitotic agents -- Health aspects
Abstract

CAR-T cell therapy is a type of cancer immunotherapy often offered to patients when other treatments have not worked. However, the US Food and Drug Administration is investigating reports that [...]

Published
2023

33. Atara Biotherapeutics expands global tab-cel partnership with Pierre Fabre Laboratories

Subjects
T cells -- Health aspects, International cooperation -- Health aspects, Immunotherapy -- Health aspects, Pharmaceuticals and cosmetics industries
Abstract

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported recent [...]

Published
2023

34. Virion Therapeutics, Ocean Biomedical begin patient dosing in phase 1b trial of VRON-0200 immunotherapy for chronic HBV infection

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Infection -- Health aspects, Hepatitis B -- Health aspects, Clinical trials -- Health aspects, Venture capital companies -- Joint ventures -- Product development, Company joint venture, Pharmaceuticals and cosmetics industries
Abstract

Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc., announced that the first patients have been dosed in the [...]

Published
2023

35. Data on Cancer Detailed by Researchers at University of Pennsylvania (Enhancing Cellular Immunotherapies In Cancer By Engineering Selective Therapeutic Resistance)

Subjects
Oncology, Experimental -- Health aspects, T cells -- Health aspects, Immunotherapy -- Health aspects, Genetic engineering -- Health aspects, Cancer -- Drug therapy -- Research, Business, Health, Health care industry, University of Pennsylvania
Abstract

2024 AUG 20 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Cancer is now available. According to news reporting out of Philadelphia, [...]

Published
2024

36. Findings from Wenzhou Medical University in the Area of Cancer Reported (Enzyme-instructed Photoactivatable Supramolecular Antigens On Cancer Cell Membranes for Precision-controlled T-cell-based Cancer Immunotherapy)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Antigens -- Health aspects, Cancer -- Care and treatment -- Drug therapy, Enzymes -- Health aspects, Cell membranes -- Health aspects, Health
Abstract

2024 JUL 10 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on Cancer are presented in a new report. According to news reporting originating [...]

Published
2024

37. Reports from University of Science and Technology China Provide New Insights into Acute Hemorrhagic Leukoencephalitis (Brief Communication Cytokine Storm Related To Cd4+t Cells In Influenza Virus-associated Acute Necrotizing Encephalopathy)

Subjects
Cytokines -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Encephalopathy -- Health aspects, T cells -- Health aspects, Swine influenza -- Health aspects, Influenza viruses -- Health aspects, Immunotherapy -- Health aspects, Encephalomyelitis -- Health aspects, Health
Abstract

2024 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A new study on Autoimmune Diseases and Conditions - Acute Hemorrhagic Leukoencephalitis is now available. [...]

Published
2024

38. Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology ASCO Annual Meeting

Subjects
T cells -- Health aspects, Trade and professional associations -- Health aspects, Metastasis -- Drug therapy, Immunotherapy -- Health aspects, Cancer -- Genetic aspects, College teachers -- Health aspects, Biomedical engineering -- Health aspects, Biotechnology industry, Health, Science and technology
Abstract

2024 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, [...]

Published
2024

39. Reports on Cancer Therapy from Columbia University Provide New Insights (Mapping Variant Effects On Anti-tumor Hallmarks of Primary Human T Cells With Base-editing Screens)

Subjects
United States. National Institutes of Health, T cells -- Health aspects, Antineoplastic agents -- Health aspects, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Antimitotic agents -- Health aspects, Health, Columbia University
Abstract

2024 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on Drugs and Therapies - Cancer Therapy. According to news reporting [...]

Published
2024

40. New Cancer Therapy Data Have Been Reported by Investigators at University of the Punjab [Cloning and Expression of Human Interleukin 2 (Il-2) In e. Coli and Its Antitumor Activity]

Subjects
T cells -- Health aspects, Skin cancer -- Drug therapy, Antineoplastic agents -- Health aspects, Immunotherapy -- Health aspects, Drug approval -- Health aspects, Interleukins -- Health aspects, Cloning -- Health aspects, Antimitotic agents -- Health aspects, Health
Abstract

2024 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Drugs and Therapies - Cancer Therapy have been published. According to [...]

Published
2024

41. Latest Therapeutic Choice for Multiple Myeloma Patients

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Multiple myeloma -- Care and treatment, Health
Abstract

2024 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- An international symposium on CAR-T therapy for hematologic malignancies was held at the Jiahui International [...]

Published
2024

42. Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Subjects
T cells -- Health aspects, Lupus -- Health aspects, Multiple sclerosis -- Health aspects, Diseases -- California, Systemic lupus erythematosus -- Health aspects, Immunotherapy -- Health aspects, B cells -- Health aspects, Business, Business, international
Abstract

ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells ATA3219 Induces Lower Levels of Pro-Inflammatory Cytokines While Maintaining Cytotoxic Potency Compared [...]

Published
2024

43. Atara Biotherapeutics Submits Tabelecleucel (Tab-cel[R]) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Diseases -- California, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Drug approval -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger [...]

Published
2024

44. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

45. INmune Bio Inc. presents data on INB03's role in treatment of high-risk breast cancer at AACR 2024

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Tumor necrosis factor -- Health aspects, Breast cancer -- Risk factors, General interest, News, opinion and commentary
Abstract

BOCA RATON: INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is presenting data on the use of [...]

Published
2024

46. INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Tumor necrosis factor -- Health aspects, Breast cancer -- Health aspects, Banking, finance and accounting industries, Business
Abstract

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=GCytWNTcYVaSYNhadgCBTNreZuO9eKl_xHmpkRZtYqs82e-3IMHpteVkDi_kxvMML5XoFqAEa92C5-mYrJW2x2ZOICsoNSw4Uztj9oIi_xQ= (NASDAQ: [...]

Published
2024

47. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

48. Dassault Systemes and CDR-Life Collaborate to Accelerate Scientific Innovation for Cancer Therapies

Subjects
Dassault Systemes S.A. -- Innovations, Euronext Paris S.A. -- Innovations, Computer software industry -- Innovations -- Health aspects, T cells -- Health aspects, Antineoplastic agents -- Innovations, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Securities industry -- Health aspects -- Innovations, Antimitotic agents -- Innovations, Securities industry, Business, Business, international
Abstract

M2 PRESSWIRE-March 13, 2024-: Dassault Systemes and CDR-Life Collaborate to Accelerate Scientific Innovation for Cancer Therapies (C)1994-2024 M2 COMMUNICATIONS RDATE:13032024 VELIZY-VILLACOUBLAY, France - - Dassault Systemes (Euronext Paris: FR0014003TT8, DSY.PA) [...]

Published
2024

49. Dassault Systemes and CDR-Life Collaborate to Accelerate Scientific Innovation for Cancer Therapies

Subjects
Dassault Systemes S.A. -- Innovations, Euronext Paris S.A. -- Innovations, T cells -- Health aspects, Antineoplastic agents -- Innovations, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Antimitotic agents -- Innovations, Business, Business, international
Abstract

* Dassault Systemes, a science-based leader in virtual twin experiences and CDR-Life, a Swiss biotherapeutics company, partnered to study the stability of antibody-based biologics * Dassault Systemes' Contract Research team [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results